PT  - JOURNAL ARTICLE
AU  - Isaac Zentner
AU  - Hyun-moon Back
AU  - Leonid Kagan
AU  - Selvakumar Subbian
AU  - Jyothi Nagajyothi
AU  - Shashikant Srivastava
AU  - Jotam Pasipanodya
AU  - Tawanda Gumbo
AU  - Gregory P. Bisson
AU  - Christopher Vinnard
TI  - Redox imbalance and oxidative DNA damage during isoniazid treatment: A clinical and translational pharmacokinetic study
AID  - 10.1101/2020.04.14.20065292
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.14.20065292
4099  - http://medrxiv.org/content/early/2020/04/17/2020.04.14.20065292.short
4100  - http://medrxiv.org/content/early/2020/04/17/2020.04.14.20065292.full
AB  - Background The potential for hepatotoxicity during isoniazid-based tuberculosis (TB) treatment presents a major challenge for TB control programs worldwide. We sought to determine whether pharmacokinetic exposures of isoniazid and its metabolites were related to cellular oxidation/reduction status and downstream markers of oxidative DNA damage.Methods We performed intensive pharmacokinetic sampling among isoniazid-treated patients to determine the relative plasma exposures of isoniazid, acetylisoniazid, hydrazine, and acetylhydrazine. Physiologically-based pharmacokinetic modeling was used to estimate liver tissue exposures during a 24-hour dosing interval for each compound. We experimentally treated HepG2 cells with isoniazid and metabolites at equimolar concentrations corresponding to these exposures for 7, 14, and 28 day periods, and performed assays related to redox imbalance and oxidative DNA damage at each timepoint. We related a urine marker of oxidative DNA damage to serum isoniazid pharmacokinetic exposures and pharmacogenetics in a clinical study.Results Among isoniazid-treated patients, serum concentrations of hydrazine and isoniazid concentrations were highly correlated. At equimolar concentrations that approximated hepatic tissue exposures during a 24-hour dosing interval, hydrazine demonstrated the highest levels of redox imbalance, mitochondrial injury, and oxidative DNA damage over a 28-day treatment period. In a clinical validation study of isoniazid-treated TB patients, peak isoniazid serum concentrations were positively associated with a urine biomarker of oxidative DNA damage.Conclusions Isoniazid and its metabolites share the potential for oxidative cellular damage, with the greatest effects observed for hydrazine. Future studies should investigate the clinical consequences of oxidative stress with regards to clinical episodes of drug induced liver injury during isoniazid treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: CV was supported by NIAID (K23AI102639, R01AI137080).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available with appropriate regulatory approvals.